GITNUX MARKETDATA REPORT 2024

Obesity Drug Industry Statistics

The obesity drug industry is expected to experience steady growth in the coming years due to the increasing prevalence of obesity worldwide.

With sources from: reportsanddata.com, apnews.com, gminsights.com, globenewswire.com and many more

Statistic 1

North America holds the largest market share of obesity drugs which is around 42.0%.

Statistic 2

The obesity drug market is projected to reach $3.4 billion by 2030, growing at a CAGR of 3.4%.

Statistic 3

Prescription obesity drugs market was valued at $1.4 billion in 2019.

Statistic 4

The market share of the Asia-Pacific region is expected to reach 14.7% by 2026.

Statistic 5

Orlistat accounted for the largest share of the obesity drugs market in 2016.

Statistic 6

By 2027, the anti-obesity medication market is projected to reach $2.6 billion.

Statistic 7

The peripherally acting drugs have the highest market share in the anti-obesity drugs market.

Statistic 8

Phentermine and topiramate are projected to reach nearly $2 billion in sales by 2022.

Statistic 9

Europe was the second largest market in the global anti-obesity drugs market in 2020.

Statistic 10

Obesity drugs industry for females is expected to grow at over 3.5% CAGR from 2021 to 2027.

Statistic 11

Prescription anti-obesity drugs could earn almost $25 billion by the mid-2020s in the U.S. alone.

Statistic 12

Centers for disease control and prevention stated over one third (36.5%) of U.S. adults have obesity, which is one of the reasons for rise in demand of obesity drugs.

Statistic 13

OTC obesity-drug market will snatch market from prescribed drugs, which will grow at a CAGR of 3.4% during the forecast period.

Statistic 14

In 2019, Phentermine and Topiramate held the largest market share of the global anti-obesity drugs market.

Statistic 15

In 2018, the FDA approved the first generic version of Xenical (orlistat) contributing to the growth of generic drugs in the anti-obesity drug market.

Statistic 16

By 2026, the global obesity drugs market is expected to garner about $14 billion, registering a CAGR of around 4.91%.

Sources Icon Sources

In this post, we explore key statistics surrounding the obesity drug industry, shedding light on market trends, projections, and significant players in the global landscape. From market shares and projected revenues to emerging trends and regional insights, these statistics provide valuable insights into the evolving dynamics of the obesity drug market.

Statistic 1

"North America holds the largest market share of obesity drugs which is around 42.0%."

Sources Icon

Statistic 2

"The obesity drug market is projected to reach $3.4 billion by 2030, growing at a CAGR of 3.4%."

Sources Icon

Statistic 3

"Prescription obesity drugs market was valued at $1.4 billion in 2019."

Sources Icon

Statistic 4

"The market share of the Asia-Pacific region is expected to reach 14.7% by 2026."

Sources Icon

Statistic 5

"Orlistat accounted for the largest share of the obesity drugs market in 2016."

Sources Icon

Statistic 6

"By 2027, the anti-obesity medication market is projected to reach $2.6 billion."

Sources Icon

Statistic 7

"The peripherally acting drugs have the highest market share in the anti-obesity drugs market."

Sources Icon

Statistic 8

"Phentermine and topiramate are projected to reach nearly $2 billion in sales by 2022."

Sources Icon

Statistic 9

"Europe was the second largest market in the global anti-obesity drugs market in 2020."

Sources Icon

Statistic 10

"Obesity drugs industry for females is expected to grow at over 3.5% CAGR from 2021 to 2027."

Sources Icon

Statistic 11

"Prescription anti-obesity drugs could earn almost $25 billion by the mid-2020s in the U.S. alone."

Sources Icon

Statistic 12

"Centers for disease control and prevention stated over one third (36.5%) of U.S. adults have obesity, which is one of the reasons for rise in demand of obesity drugs."

Sources Icon

Statistic 13

"OTC obesity-drug market will snatch market from prescribed drugs, which will grow at a CAGR of 3.4% during the forecast period."

Sources Icon

Statistic 14

"In 2019, Phentermine and Topiramate held the largest market share of the global anti-obesity drugs market."

Sources Icon

Statistic 15

"In 2018, the FDA approved the first generic version of Xenical (orlistat) contributing to the growth of generic drugs in the anti-obesity drug market."

Sources Icon

Statistic 16

"By 2026, the global obesity drugs market is expected to garner about $14 billion, registering a CAGR of around 4.91%."

Sources Icon

Interpretation

The statistics presented shed light on the current landscape and future projections of the obesity drug industry. North America dominates the market share, with significant growth anticipated globally, particularly in Asia-Pacific. The market is evolving, with different medications gaining prominence, such as peripherally acting drugs and generic versions. The industry's growth is strongly influenced by factors like rising obesity rates, regulatory approvals, and the shifting preference towards OTC medications. These trends highlight a lucrative and dynamic market environment, indicating substantial opportunities for key players in the obesity drug industry to capitalize on in the coming years.

Can You Trust Our Report?

The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.

Learn more about our process here.

Submit Your Own Statistic Data

Would you like to submit your own researched statistics on this topic? You are welcome to use the form below and submit your suggestion to us. We will check the source and approve it if necessary.

... Before You Leave, Catch This! 🔥

Your next business insight is just a subscription away. Our newsletter The Week in Data delivers the freshest statistics and trends directly to you. Stay informed, stay ahead—subscribe now.

Sign up for our newsletter and become the navigator of tomorrow's trends. Equip your strategy with unparalleled insights!